Skip to main content
48°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
HilleVax, Inc. - Common Stock
(NQ:
HLVX
)
12.81
-0.17 (-1.31%)
Official Closing Price
Updated: 4:15 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about HilleVax, Inc. - Common Stock
< Previous
1
2
Next >
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
March 20, 2024
HLVX stock results show that HilleVax beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Recap: HilleVax Q4 Earnings
March 20, 2024
Via
Benzinga
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
March 20, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
February 05, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
January 18, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax: Q1 Earnings Insights
May 12, 2023
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
January 08, 2024
Collaboration leverages HilleVax’s leading norovirus vaccine development expertise and adds a Phase 1-ready next-generation program to HilleVax’s pipeline
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at Upcoming Investor Conferences
November 01, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 26, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 25, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
Why HilleVax Shares Are Trading Lower
September 20, 2023
HilleVax Inc (NASDAQ: HLVX) shares are trading lower by 8.5% to $13.20 Wednesday morning after the company announced pricing of its previously-announced public offering of comm
Via
Benzinga
HilleVax Announces Pricing of Public Offering of Common Stock
September 19, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 19, 2023
Via
Benzinga
HilleVax Announces Proposed Public Offering of Common Stock
September 19, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 14, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 12, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
May 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
April 25, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
March 17, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Executive Management Appointments and Promotions
January 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
December 05, 2022
From
HilleVax, Inc.
Via
GlobeNewswire
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
November 22, 2022
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
HilleVax to Participate in November Investor Conferences
November 10, 2022
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 10, 2022
From
HilleVax, Inc.
Via
GlobeNewswire
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
October 26, 2022
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 21, 2022
Gainers
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.